SCHEMBL2913348

SCHEMBL2913348

CN(C)S(=O)(=O)c1ccc2c(C(=O)O)c[nH]c(=O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.50
▸ LMNA P02545 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HPGD P15428 2/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ AKR1B1 P15121 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ ADRB2 P07550 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ HRH1 P35367 1/20 0.44
▸ CCR3 P51677 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ GAA P10253 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922964 0.84 KDM4E (0.54) KDM4ELMNAHPGDHSD17B10MEN1
SCHEMBL2922360 0.82 KDM4E (0.56) KDM4EHPGDHSD17B10MEN1KMT2A
SCHEMBL2916302 0.81 KDM4E (0.54) KDM4ELMNAHPGDHSD17B10MEN1
SCHEMBL2920920 0.81 KDM4E (0.54) KDM4ELMNAHPGDHSD17B10MEN1
SCHEMBL2923292 0.81 KDM4E (0.50) KDM4ELMNAHPGDHSD17B10MEN1
SCHEMBL2916325 0.78 KDM4E (0.54) KDM4ELMNAHPGDHSD17B10MEN1
SCHEMBL3248232 0.78 HSD17B10 (0.47) KDM4ELMNAHTTHPGDHSD17B10
SCHEMBL3282728 0.75 GAA (0.58) KDM4ELMNAHTTHPGDHSD17B10
SCHEMBL3282624 0.74 KDM4E (0.52) KDM4ELMNAHSD17B10MEN1KMT2A
SCHEMBL3282678 0.74 PARG (0.50) KDM4ELMNAHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 — — EP disclosed
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 — — EP disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 KDM4E 1685/4885LMNA 4760/4885HTT 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback